Strategy for incorporating molecular and cytogenetic markers into acute myeloid leukemia therapy.
Acute myeloid leukemia is a heterogeneous disease. Standard treatments may be applied to biologically distinct subgroups, resulting in different treatment outcomes. The concept of risk-adapted therapy allows for recognition of this biologic diversity by incorporating key biologic features, such as cytogenetic and molecular markers, when formulating treatment regimens and investigating emerging targeted therapies based on disease characteristics.
Frattini
Mark G
MG
Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Maslak
Peter G
PG
D014408:Biomarkers, Tumor / Q000235:genetics*; D005819:Genetic Markers / Q000235:genetics*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000628:therapy*; D011379:Prognosis
D014408:Biomarkers, Tumor; D005819:Genetic Markers